Using Medical Claims for Policy Effectiveness Surveillance: Reimbursement and Utilization of Abdomen/Pelvis Computed Tomography Scans-Reference-Cited by-同舟云学术

Using Medical Claims for Policy Effectiveness Surveillance: Reimbursement and Utilization of Abdomen/Pelvis Computed Tomography Scans

Published:2015-03-09 Issue:6 Volume:50 Page:1910-1926
ISSN:0017-9124
Container-title:Health Services Research
language:en
Short-container-title:Health Serv Res

Author:

Horný Michal¹,Morgan Jake R.¹,Merker Vanessa L.¹^ORCID

Affiliation:

1. Department of Health Policy and Management; Boston University School of Public Health; Boston MA

Publisher

Wiley

Subject

Health Policy

Reference27 articles.

1. Professional Component Payment Reductions for Diagnostic Imaging Examinations When More Than One Service Is Rendered by the Same Provider in the Same Session: An Analysis of Relevant Payment Policy;Allen;Journal of the American College of Radiology,2011

2. Radiology's Ethical Responsibility for Healthcare Reform: Tempering the Overutilization of Medical Imaging and Trimming Down a Heavyweight;Armao;Journal of Magnetic Resonance Imaging,2012

3. Tight Squeeze: Imaging is Facing Ever-Closer Scrutiny on Reimbursement and Utilization. Is a New Role for Radiologists in the Making?;Baldwin;Health Data Management,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication and procedural abortion uptake during a period of increasing abortion hostility;Social Science & Medicine;2024-09

2. Decomposition of medical imaging spending growth between 2010 and 2021 in the US employer–insured population;Health Affairs Scholar;2024-03-01

3. Safety of Utilizing Ultrasound as the Sole Modality of Follow-Up after Endovascular Aneurysm Repair;Annals of Vascular Surgery;2023-05

4. Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series;Human Vaccines & Immunotherapeutics;2023-01-02

5. HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US;Human Vaccines & Immunotherapeutics;2023-01-02